Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Paradigm BioCapital and related reporting persons disclosed beneficial ownership positions in Erasca, Inc. common stock. Paradigm BioCapital Advisors LP/GP and Senai Asefaw report 10,392,702 shares (representing 3.3% of the class) as of the close of business on March 31, 2026. The filing shows Paradigm BioCapital International Fund Ltd. directly owns 9,157,687 shares (2.9%).
The percentages use a share base of 310,806,888 shares outstanding as of March 31, 2026, cited from the issuer's Form 10-Q filed May 11, 2026. Reporting persons disclaim ownership except for the shares they directly beneficially own; the Adviser is identified as investment manager of the Fund and related accounts.
T. Rowe Price Investment Management reports beneficial ownership in ERASCA INC. As of 03/31/2026 the filing shows 21,224,264 shares beneficially owned, representing 6.8% of the class. The filer discloses sole voting power over 20,502,610 shares and sole dispositive power over 21,224,264 shares.
The filing is an amendment to a Schedule 13G/A and includes a signed affirmation dated 05/15/2026.
Erasca, Inc. Schedule 13G: RTW Investments, LP and Roderick Wong report shared beneficial ownership of 16,157,175 shares of Erasca common stock, representing 5.2% of the class based on 310,799,547 shares outstanding as of March 5, 2026. The filing shows shared voting and dispositive power over these shares held by the RTW Funds. The statement is signed by Dr. Wong on May 15, 2026.
Erasca, Inc. Schedule 13G/A amendment discloses institutional beneficial ownership positions held by advisory clients of Suvretta Capital Management, LLC and related parties. Suvretta reports 3,434,967 shares (1.1%) held with shared voting and dispositive power; Averill Master Fund, Ltd. reports 2,945,497 shares (0.9%).
The filing states all reported securities are directly owned by Suvretta advisory clients and that none of those clients is separately deemed to beneficially own more than 5% of the class. Shared voting and shared dispositive power are asserted for the listed holders; sole voting and sole dispositive power are reported as zero.
Erasca, Inc. reported first‑quarter 2026 results marked by a much larger net loss as it doubled down on its RAS/MAPK cancer franchise. Net loss widened to $183.4 million, or $0.60 per share, from $31.0 million a year earlier, mainly due to recording $150.0 million of in‑process research and development expense for expanding territorial rights under its Joyo pan‑RAS license.
Research and development spending excluding that item was $27.3 million, with $13.8 million for ERAS‑0015 and $6.7 million for ERAS‑4001, while general and administrative expense was $10.6 million. A January 2026 underwritten equity offering generated net proceeds of $242.7 million, helping lift total cash, cash equivalents, and marketable securities to $408.5 million and total assets to $461.2 million. The company now expects this liquidity to fund operations into the second half of 2028.
Erasca continues to advance ERAS‑0015 and ERAS‑4001 through early‑stage trials and has stopped development of naporafenib, terminating its Novartis license effective June 3, 2026. Management reiterates that product revenue is not expected for several years, and future funding will likely continue to rely on capital markets and partnering.
Erasca, Inc. reported first‑quarter 2026 results marked by a much larger net loss as it doubled down on its RAS/MAPK cancer franchise. Net loss widened to $183.4 million, or $0.60 per share, from $31.0 million a year earlier, mainly due to recording $150.0 million of in‑process research and development expense for expanding territorial rights under its Joyo pan‑RAS license.
Research and development spending excluding that item was $27.3 million, with $13.8 million for ERAS‑0015 and $6.7 million for ERAS‑4001, while general and administrative expense was $10.6 million. A January 2026 underwritten equity offering generated net proceeds of $242.7 million, helping lift total cash, cash equivalents, and marketable securities to $408.5 million and total assets to $461.2 million. The company now expects this liquidity to fund operations into the second half of 2028.
Erasca continues to advance ERAS‑0015 and ERAS‑4001 through early‑stage trials and has stopped development of naporafenib, terminating its Novartis license effective June 3, 2026. Management reiterates that product revenue is not expected for several years, and future funding will likely continue to rely on capital markets and partnering.
Erasca reported first quarter 2026 results highlighting major investment in its RAS-targeting pipeline. The company ended March 31, 2026 with $408.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028.
Total operating expenses rose to $187.9 million, driven by $150.0 million of in-process R&D expense to obtain worldwide rights to ERAS-0015, alongside $27.3 million in R&D and $10.6 million in G&A. Net loss widened to $183.4 million, or $(0.60) per share.
Strategically, Erasca advanced ERAS-0015 and ERAS-4001, signed clinical trial collaborations with Merck and Tango Therapeutics, secured a U.S. composition of matter patent for ERAS-4001 through June 2043, expanded ERAS-0015 licensing territory, and completed an upsized public offering raising approximately $258.8 million in gross proceeds.
Erasca reported first quarter 2026 results highlighting major investment in its RAS-targeting pipeline. The company ended March 31, 2026 with $408.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028.
Total operating expenses rose to $187.9 million, driven by $150.0 million of in-process R&D expense to obtain worldwide rights to ERAS-0015, alongside $27.3 million in R&D and $10.6 million in G&A. Net loss widened to $183.4 million, or $(0.60) per share.
Strategically, Erasca advanced ERAS-0015 and ERAS-4001, signed clinical trial collaborations with Merck and Tango Therapeutics, secured a U.S. composition of matter patent for ERAS-4001 through June 2043, expanded ERAS-0015 licensing territory, and completed an upsized public offering raising approximately $258.8 million in gross proceeds.
Erasca, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only webcast at 11:30 a.m. Pacific Time on June 26, 2026. Holders of 310,965,971 shares of common stock as of April 27, 2026 may vote.
Stockholders will elect three Class II directors (Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.) and vote on ratifying KPMG LLP as independent registered public accounting firm for 2026. The proxy also details board governance practices and 2025 executive pay, including CEO Jonathan Lim’s total compensation of $4.3 million and sizable stock option grants.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.